Using methylation patterns to classify solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will collect tumor tissue from 180 patients (60 CNS tumors, 60 endometrial carcinomas, 60 endocrine tumors) and extract DNA from FFPE sections. Samples will undergo targeted NGS and genome-wide DNA methylation profiling using Illumina arrays to generate methylome data. Researchers will correlate methylation-based tumor classes with clinical parameters, treatment responses, and survival to identify clinically relevant subgroups. The team plans to develop interdisciplinary diagnostic protocols to implement methylation-based classification in routine pathology workflows.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of one of the following types of cancer: gliomas, malignant thyroid neoplasms, or endometrial carcinomas (according to the WHO Nomenclature)
* Availability of adequate material for analysis at the laboratory, specifically availability of at least 3 sections of 10 µm of FFPE

Exclusion Criteria:

* no

Where it's running

• IRCCS Azienda Ospedaliero Univesitaria di Bologna
  Bologna, Bo, Italy Recruiting

Study contacts

• Study coordinator: Giovanni Tallini, Prof.
• Email: giovanni.tallini@ausl.bologna.it
• Phone: +39 338 9763329

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urine samples from adults with solid cancers to explore chemistry linked to nearing end of life

  This study tests urine chemistry in adults with solid tumors to see if it reflects how close a patient is to death.

  Recruiting The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, Merseyside · NCT07848997

• Tempus Open Link registry for cancer patients using Olivia platform

  This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.

  Recruiting Tempus AI · Chicago, Illinois · NCT07756034

• Metronomic low-dose gemcitabine, mitomycin C, and thalidomide for advanced solid tumors

  This phase II trial tests a low-dose, continuously given combo of gemcitabine, mitomycin C, and thalidomide in adults with advanced solid tumors to see if it helps control the disease.

  Recruiting Phase 2 Sarcoma Oncology Research Center, LLC · Santa Monica, California · NCT07671534

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• JL19001 Injection Alone or with Standard Therapy in Advanced Solid Tumors or Relapsed/Refractory B-Cell NHL

  This phase 1 trial tests JL19001 by itself or with standard treatment to see if it is safe and tolerable in adults with advanced solid tumors or relapsed/refractory B-cell non-Hodgkin lymphoma.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07603479

• Phase 1 dose-escalation and expansion test of IUAb190708 for advanced or recurrent solid tumors

  This trial tests IUAb190708, a new cytotoxic anti–PD‑L1 antibody given by IV, to see if it is safe and can kill tumors in adults with advanced or recurrent solid cancers.

  Recruiting at 6 sites Phase 1 ImmunoUrchin · Fuzhou, Fujian and 5 other locations · NCT07584954

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.